|
|
News Breaks | | | | September 20, 2012 | | 08:21 EDT |  | IDIX | FDA requests additional data from Idenix on hepatitis C treatments
Idenix Pharmaceuticals disclosed in a regulatory filing that, as previously reported, the company received verbal notices from the U.S. Food and Drug Administration in August that a partial clinical hold has been placed on IDX184 and that a clinical hold has been placed on IDX19368, which are both under development for the treatment of hepatitis C virus, due to the occurrence of a serious cardiac-related adverse event encountered with a competitor’s nucleotide polymerase inhibitor for the treatment of HCV. Idenix said that the FDA has subsequently requested in writing additional data related to IDX184 and IDX19368. The company has updated its general investor presentation to provide a summary of such requested additional data and the status of data collection with respect to IDX184. | |
|
News For IDIX From The Last 14 Days Check below for free stories on IDIX the last two weeks. |
|
|
| June 7, 2013 | | 11:55 EDT |  | IDIX | High option volume stocks: FXB CTRX CA IDIX
 Subscribe for More Information | |
|
|
|
|
|
|
